Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
saRNA Ebola vaccine
- Development stage
- Unknown
- Lead developer
- Imperial College London
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The saRNA Ebola vaccine is a self-amplifying ribonucleic acid (saRNA) vaccine candidate developed by Imperial College London for the prevention of Ebola virus disease. Utilizing a self-amplifying RNA platform derived from an alphavirus backbone (typically Venezuelan Equine Encephalitis Virus), the vaccine encodes both the Ebola virus glycoprotein (GP) antigen and a viral replicase complex. Upon intramuscular administration, the replicase enables the intracellular amplification of the antigenic RNA transcript, leading to sustained and high-level expression of the Ebola GP. This mechanism is designed to elicit robust humoral and cellular immune responses at significantly lower doses compared to conventional mRNA vaccines. The vaccine is currently being evaluated in a Phase I clinical trial (NCT05370014) alongside similar saRNA candidates for Marburg virus and Lassa fever, with funding from the Coalition for Epidemic Preparedness Innovations (CEPI).
- Other names
- self-amplifying RNA Ebola vaccineImperial Ebola saRNA vaccine
02
Targets
Zaire ebolavirus glycoproteinInnate immune RNA sensor
Beyond the preview
Go deeper on saRNA Ebola vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on saRNA Ebola vaccine.